| Popis: |
Tristan Ferry,1 Charalambos Gogos,2 Alex Soriano,3 Francesco Blasi,4,5 Wajeeha Ansari,6 Michal Kantecki,7 Bernd Schweikert,8 Gustavo Luna,9 Matteo Bassetti10 1Infectious Diseases Department, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France; 2Division of Infectious Diseases, Department of Internal Medicine, University of Patras, Patras, Greece; 3Infectious Diseases Department, Hospital Clínic de Barcelona, CIBERINF, CIBER in Infectious Diseases, Barcelona, Spain; 4Respiratory Unit and Cystic Fibrosis Center, Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; 5Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; 6Pfizer Biopharmaceuticals Group, Pfizer Inc., New York, NY, USA; 7Global Medical Affairs, Pfizer International Operations, Pfizer, Paris, France; 8Health Economics and Epidemiology, ICON plc, Munich, Germany; 9Health Economics and Epidemiology, ICON plc, Stockholm, Sweden; 10Infectious Diseases, Clinica Malattie Infettive, Ospedale Policlinico IRCCS San Martino and University of Genoa, Genoa, ItalyCorrespondence: Wajeeha Ansari, Pfizer Inc., 66 Hudson Blvd E, New York, NY, 10001, USA, Email wajeeha.ansari@pfizer.comBackground: Ceftaroline fosamil is approved for the treatment of complicated skin and soft tissue infections (cSSTI) and community-acquired pneumonia (CAP); however, data on its real-world use and effectiveness in Europe and Latin America are currently limited. This retrospective observational study assessed ceftaroline fosamil use and treatment outcomes in adults hospitalized with cSSTI or CAP treated with ceftaroline fosamil in a usual care setting in Europe and Latin America. Results for patients with cSSTI are reported.Methods: Data from patients with cSSTI who received ≥ 4 consecutive intravenous ceftaroline fosamil doses up to May 31, 2019, were collected from sites in Brazil, Colombia, France, Greece, Italy, and Spain. Patient characteristics, clinical management, hospitalization information, microbiological diagnosis, and clinical responses were summarized descriptively. Healthcare resource use variables were evaluated by clinical response to ceftaroline fosamil.Results: Data for 132 patients were included (58.3% male; mean age 58.5 years). Most common lesions were cellulitis/fasciitis (62.1%), abscess (34.1%), and post-surgical wounds (19.7%). Pathogens most frequently identified were methicillin-resistant (18.2%) and methicillin-susceptible Staphylococcus aureus (17.4%). Median (range) ceftaroline fosamil treatment duration was 8 (2– 60) days (daily doses of 1200 [400– 2400] mg); 78 patients (59.1%) received monotherapy. In total, 75 (56.8%) patients had additional antibiotics after ceftaroline fosamil. Clinical response occurred in 118 (89.4%) patients. All-cause 30-day readmission occurred in 13 (9.8%) patients, and all-cause 30-day mortality in 7 (5.3%). Clinical response to ceftaroline was associated with > 25% shorter length of hospital and intensive care stay, and with ~40% lower hospital costs, versus non-responders.Conclusion: Ceftaroline fosamil was effective in treating adults with cSSTI and clinical response to ceftaroline fosamil was associated with reductions in healthcare resource use compared with non-responders, in Europe and Latin America.Clinicaltrials.gov Identifier: NCT04198571.Keywords: antibiotics, real-world evidence, efficacy, healthcare resource use |
